# A Drug Interaction Study of SY-004 Capsules in Healthy Subjects

> **NCT04907019** · PHASE1 · COMPLETED · sponsor: **Suzhou Yabao Pharmaceutical R&D Co., Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** rifampicin，SY-004

## Key facts

- **NCT ID:** NCT04907019
- **Lead sponsor:** Suzhou Yabao Pharmaceutical R&D Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-06
- **Primary completion:** 2021-08-17
- **Final completion:** 2021-08-17
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2022-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04907019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04907019, "A Drug Interaction Study of SY-004 Capsules in Healthy Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04907019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*